Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907417 | 0.85 | PREP (0.32) | ALDH1A1CA12CA1CA9 | |
| SCHEMBL6906689 | 0.78 | MEN1 (0.40) | ALDH1A1MAPTCA12CA1CA9 | |
| SCHEMBL6905294 | 0.76 | CYP1A1 (0.43) | CYP1A2 | |
| SCHEMBL6905296 | 0.76 | CYP1A1 (0.43) | CYP1A2 | |
| SCHEMBL5042411 | 0.76 | ALDH1A1 (0.33) | ALDH1A1MAPTCA12CA1CA9 | |
| SCHEMBL6904874 | 0.76 | CA1 (0.32) | ALDH1A1CA12CA1CA9 | |
| SCHEMBL9839418 | 0.75 | HPGD (0.34) | CA12CA1CA9 | |
| SCHEMBL9906779 | 0.75 | ALOX5AP (0.35) | CA12CA1CA9 | |
| SCHEMBL5139277 | 0.74 | ALDH1A1 (0.40) | ALDH1A1MAPTL3MBTL1POLBCA1 | |
| SCHEMBL5179449 | 0.73 | LMNA (0.42) | ALDH1A1MAPTL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | ALDH1A1 553/4885MAPT 4379/4885L3MBTL1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.